about
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisEULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateDiacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEOUse of Intra-Articular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice.Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohortHigh levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort.Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaborationEULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration.EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional studyHighest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.Natural selection and population history in the human angiotensinogen gene (AGT): 736 complete AGT sequences in chromosomes from around the world.Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus.Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsThe role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacemenAssociation of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis.Complex analysis of urate transporters SLC2A9, SLC22A12 and functional characterization of non-synonymous allelic variants of GLUT9 in the Czech population: no evidence of effect on hyperuricemia and gout.Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials.Physiological effects of oral glucosamine on joint health: current status and consensus on future research prioritiesAbatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis.The association between lean mass and bone mineral content in the high disease activity group of adult patients with juvenile idiopathic arthritis.Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis.Consensus statement on the use of rituximab in patients with rheumatoid arthritisOARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group.Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.Measurement of structural progression in osteoarthritis of the hip: the Barcelona consensus group.Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis.Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis.Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis.Pentosidine, an advanced glycation end-product, may reflect clinical and morphological features of hand osteoarthritis
P50
Q24603648-BECEDED0-10C5-4380-9231-ADF465B26126Q24674132-C5843312-C7B3-4C4B-A994-FF3883775FADQ26859134-AAD3625F-32A0-44A8-9B81-7BEA2B04EFEBQ28079515-9F56F695-0F53-48F4-9443-E4EA3F2BA9DBQ30238805-6CCA23C1-BC60-4406-9D09-9485D7CB0C16Q30839061-2A3F6A37-2068-42E3-8C1A-069312AFF1F7Q30876263-C4EF3D74-CF92-423B-A4FF-53AE0DC33911Q31046441-04A2872A-D67E-41AF-93B5-CE941BC15042Q31119321-ECC96DAC-68B6-4F6C-93C1-A9C81D8034E5Q31154802-F7BD7757-D8F1-478F-A519-5A73DDF2DF68Q33260652-A8330FA0-394A-4AE6-82CE-6FD4EBAE29F0Q33610284-103E421E-D199-46FE-A2A1-675A314254FBQ33899815-7FDF9A01-430F-4823-AAEC-1C90D5E179C5Q33909877-54876578-8236-4E3D-8C67-A941C5826D0BQ33976382-911F3146-E4D2-4ECC-855C-D943D573A33AQ34061733-2B634636-A4A8-44BB-9BE0-5023178DF6F2Q34091615-C91AE92F-D603-4200-9C09-5091BE2A382DQ34110066-C95CFF5A-36E6-4C84-A4A0-F4C6C15DCC11Q34118968-E01C79BB-6149-42DE-9A29-BFD2990864CFQ34237586-5AC85CCE-E177-458E-8D9F-A77611655B15Q34276637-425504DC-ABC7-4FE4-AE76-79A0550C958AQ34537434-8FC2943A-6E98-4C11-92FA-B732C281E678Q34581685-8DADA2BF-1926-442D-9453-8A4B4E1E9CC4Q34636799-B0E7DCBB-BBA3-4786-8682-98162380D838Q34752154-ABD2AA9F-0390-433B-B867-B1C34536D5C5Q35003750-20C6ADCD-3E4B-429D-B843-1FA65B5106F7Q35099938-D49B3B9D-D34B-4DBE-883B-7CE35CB82FA4Q35143956-3B709AF0-29CC-46AB-8068-3DFC9B707E8AQ35549064-E79EA60F-8009-490C-80B9-EB9D45DDA51BQ35554739-5F5DF703-2244-4DA9-85E0-9F985DCE40DAQ35605474-806D52E5-D0AA-47FE-BAE4-A3BA91FB4FAAQ35617658-63AD7DD6-841A-42A0-BE74-4680AEFEDEDAQ35638676-4D2C1230-F03E-4CA3-B366-C3F461557E28Q35678507-FA425F63-97ED-4AA9-A026-EC4F2D931819Q35740447-243A28E1-5C7B-4699-9D96-7BA0878A7AD3Q35818529-BA312BA3-91C1-4ECE-9C2B-EE24910D3BD9Q35882730-98C43F71-8F02-45DC-A266-4EB27121D76FQ35962863-AACBDCB7-EF8B-4E69-8C47-FC7ECEDD8423Q36003672-7BADE3E5-FE94-4E54-931F-E20D3BB87B93Q36041246-6F9F852E-27D6-4233-B517-43CA606E8CB4
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Karel Pavelka
@ast
Karel Pavelka
@en
Karel Pavelka
@es
Karel Pavelka
@nl
Karel Pavelka
@sl
type
label
Karel Pavelka
@ast
Karel Pavelka
@en
Karel Pavelka
@es
Karel Pavelka
@nl
Karel Pavelka
@sl
prefLabel
Karel Pavelka
@ast
Karel Pavelka
@en
Karel Pavelka
@es
Karel Pavelka
@nl
Karel Pavelka
@sl
P1053
E-6578-2017
P106
P1153
7102694645
P21
P31
P3829
P496
0000-0003-1952-8422